| Identification | Back Directory | [Name]
Nivolumab | [CAS]
946414-94-4 | [Synonyms]
Opdivo
MDX 1106
ONO 4538
Nivolumab
BMS 936558
Nivolumab 10mg/ml
Nivolumab USP/EP/BP
Nivolumab (anti-PD-1) |
| Hazard Information | Back Directory | [Clinical Use]
Monoclonal antibody:
Treatment of advanced (unresectable or metastatic)
melanoma, non-small cell lung cancer, renal cell
carcinoma, classical Hodgkin lymphoma, squamous
cell cancer of the head and neck and urothelial
carcinoma | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use | [Metabolism]
The metabolic pathway of nivolumab has not been
investigated. It is expected to be degraded into small
peptides and amino acids via catabolic pathways in the
same way as endogenous IgG |
|
|